Collaboration on Metalloprotease Inhibitor Drugs
By Biotechdaily staff writers
Posted on 05 Apr 2004
A collaborative agreement has been announced that is designed to advance the development of metalloprotease inhibitor drugs, which target diseases that involve the extracellular matrix, such as atherosclerosis, rheumatoid arthritis, and Alzheimer's disease.Posted on 05 Apr 2004
Protein Mechanics Inc. (Mountain View, CA, USA) will utilize its Imagiro predictive simulation technology to assist the drug design and development activities of Aventis (Strasbourg, France) by providing critical information about target-ligand interactions, novel binding sites, binding modes, mechanisms of action, and induced-fit conformational changes.
"Aventis has a strong record of commitment and accomplishment in the development of novel therapeutics for important disease areas, so we are extremely gratified that it has chosen Protein Mechanics as a partner in this effort,” said Ken Haas, president and CEO of Protein Mechanics, Inc. "We have been particularly impressed with Aventis' work in selective metalloprotease inhibition, and their expertise in applying novel technologies to critical aspects of drug discovery, so we are highly energized by the onset of our collaboration.”
Related Links:
Protein Mechanics Inc.
Aventis